EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis

Vaibhavi Joshi iD, Andrew Stacey, Yufan Feng iD, Priyakshi Kalita-de Croft iD, Pascal Hg Duijf iD, Peter T Simpson iD, Sunil R Lakhani iD, Amy E McCart Reed iD

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/2056-4538.12364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Vaibhavi Joshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Biomarkers, Tumor, Cell Cycle Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain metastases are secondary brain tumours characterised by their aggressive nature and poor prognosis. Breast cancer is one of the most common primary tumours in women to spread to the brain. A lack of biomarkers predicting likely spread to the brain and limited therapeutic interventions represents major areas of clinical unmet need. We investigated N‐myc downregulated gene‐1 (NDRG1) as a clinically relevant biomarker in breast cancer brain metastasis patients. NDRG1 expression was investigated using immunohistochemistry on tissue microarrays of two clinical cohorts: (i) brain metastatic breast cancers ( n = 48) and brain metastases ( n = 64; including a subset of 39 patient‐matched breast and brain metastasis cases) and (ii) unselected primary breast cancers ( n = 336). NDRG1 was highly expressed in breast‐to‐brain metastases, as well as in high‐grade primary breast cancers. High NDRG1 expression and also an absence of expression were associated with worse survival outcomes in both breast cancer and breast cancer brain metastasis patients. This establishes NDRG1 as a ‘Goldilocks’ protein, where too much or too little has a negative effect on survival. We pose that this accounts for its previous categorisation as both tumour suppressor and oncoprotein. Additionally, a shift in NDRG1 localisation with a gain of nuclear expression was seen at the brain metastasis stage. Significant survival benefit in cases expressing cytoplasmic NDRG1 was observed, whereas NDRG1 localisation in the nucleus showed a clear association with poorer survival. In vitro analyses revealed that hypoxic stress significantly elevated NDRG1 expression and resulted in its nuclear localisation. Our findings suggest NDRG1 expression and subcellular localisation are clinically relevant biomarkers for poor prognosis in breast cancer and breast cancer brain metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrain NeoplasmsBiomarkers, TumorCell Cycle ProteinsIntracellular Signaling Peptides and ProteinsHumansFemalePrognosisMiddle AgedAdultAgedImmunohistochemistryTissue Array AnalysisN-myc Downstream-Regulated Gene 1 Protein

Stichwörter der Autor:innen

GoldilocksNDRG1biomarkerbrain metastasisbreast cancerprognosis

Substanzen

Biomarkers, TumorCell Cycle ProteinsIntracellular Signaling Peptides and ProteinsN-myc Downstream-Regulated Gene 1 Protein

Autor:innen und Institutionen

  • UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Centre for Cancer Biology, Clinical and Health Sciences, University of South Australia & SA Pathology, Adelaide, Australia.
  • Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane, Australia.

ORCID-Profile: Vaibhavi Joshi, Yufan Feng, Priyakshi Kalita-de Croft, Pascal Hg Duijf, Peter T Simpson, Sunil R Lakhani, Amy E McCart Reed

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Joshi, V., Stacey, A., Feng, Y., Kalita-de Croft, P., Duijf, P. H., Simpson, P. T., Lakhani, S. R., & McCart Reed, A. E. (2024). NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.12364

Vancouver

Joshi V, Stacey A, Feng Y, Kalita-de Croft P, Duijf PH, Simpson PT, et al. NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/2056-4538.12364

BibTeX
@article{Joshi2024,
  author = {Joshi, Vaibhavi and Stacey, Andrew and Feng, Yufan and Kalita-de Croft, Priyakshi and Duijf, Pascal Hg and Simpson, Peter T and Lakhani, Sunil R and McCart Reed, Amy E},
  title = {NDRG1 is a prognostic biomarker in breast cancer and breast cancer brain metastasis},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/2056-4538.12364}
}
Kostenlos starten →